MTVA
Price
$1.03
Change
-$0.00 (-0.00%)
Updated
Sep 23 closing price
Capitalization
24.92M
NERV
Price
$2.09
Change
+$0.01 (+0.48%)
Updated
Sep 23 closing price
Capitalization
14.59M
47 days until earnings call
Interact to see
Advertisement

MTVA vs NERV

Header iconMTVA vs NERV Comparison
Open Charts MTVA vs NERVBanner chart's image
MetaVia
Price$1.03
Change-$0.00 (-0.00%)
Volume$327.82K
Capitalization24.92M
Minerva Neurosciences
Price$2.09
Change+$0.01 (+0.48%)
Volume$15.4K
Capitalization14.59M
MTVA vs NERV Comparison Chart in %
Loading...
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MTVA vs. NERV commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTVA is a Hold and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (MTVA: $1.03 vs. NERV: $2.09)
Brand notoriety: MTVA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MTVA: 14% vs. NERV: 55%
Market capitalization -- MTVA: $24.92M vs. NERV: $14.59M
MTVA [@Biotechnology] is valued at $24.92M. NERV’s [@Biotechnology] market capitalization is $14.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MTVA’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 1 green FA rating(s).

  • MTVA’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 1 green, 4 red.
According to our system of comparison, MTVA is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MTVA’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 5 bullish TA indicator(s).

  • MTVA’s TA Score: 5 bullish, 4 bearish.
  • NERV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MTVA is a better buy in the short-term than NERV.

Price Growth

MTVA (@Biotechnology) experienced а -22.56% price change this week, while NERV (@Biotechnology) price change was -3.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Reported Earning Dates

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MTVA($24.9M) has a higher market cap than NERV($14.6M). NERV YTD gains are higher at: -6.072 vs. MTVA (-49.261). NERV has higher annual earnings (EBITDA): 11.2M vs. MTVA (-20.01M). MTVA has more cash in the bank: 17.6M vs. NERV (15.2M). NERV has less debt than MTVA: NERV (0) vs MTVA (98K). MTVA (0) and NERV (0) have equivalent revenues.
MTVANERVMTVA / NERV
Capitalization24.9M14.6M171%
EBITDA-20.01M11.2M-179%
Gain YTD-49.261-6.072811%
P/E RatioN/A1.41-
Revenue00-
Total Cash17.6M15.2M116%
Total Debt98K0-
FUNDAMENTALS RATINGS
MTVA vs NERV: Fundamental Ratings
MTVA
NERV
OUTLOOK RATING
1..100
9259
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4161
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (33) in the Biotechnology industry is in the same range as MTVA (48) in the null industry. This means that NERV’s stock grew similarly to MTVA’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MTVA (100) in the null industry. This means that NERV’s stock grew similarly to MTVA’s over the last 12 months.

MTVA's SMR Rating (99) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that MTVA’s stock grew similarly to NERV’s over the last 12 months.

MTVA's Price Growth Rating (41) in the null industry is in the same range as NERV (61) in the Biotechnology industry. This means that MTVA’s stock grew similarly to NERV’s over the last 12 months.

MTVA's P/E Growth Rating (52) in the null industry is somewhat better than the same rating for NERV (100) in the Biotechnology industry. This means that MTVA’s stock grew somewhat faster than NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MTVANERV
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLX6.580.17
+2.65%
Helix Energy Solutions Group
FDX233.703.58
+1.56%
FedEx Corp
M17.130.24
+1.42%
Macy's
AXTI4.80-0.34
-6.61%
AXT
CUPR1.14-0.11
-8.80%
Cuprina Holdings (Cayman) Limited

MTVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MTVA has been loosely correlated with LQDA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MTVA jumps, then LQDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MTVA
1D Price
Change %
MTVA100%
N/A
LQDA - MTVA
44%
Loosely correlated
-1.97%
ARGX - MTVA
43%
Loosely correlated
-0.76%
SPRB - MTVA
34%
Loosely correlated
-6.39%
NERV - MTVA
30%
Poorly correlated
+0.32%
KPRX - MTVA
29%
Poorly correlated
-2.68%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with ASPHF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then ASPHF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+0.32%
ASPHF - NERV
44%
Loosely correlated
N/A
DNLI - NERV
35%
Loosely correlated
-2.03%
ANAB - NERV
33%
Loosely correlated
-2.10%
TCRX - NERV
32%
Poorly correlated
+1.12%
GBIO - NERV
32%
Poorly correlated
-0.86%
More